UNSPSC 51386404: Balsalazide sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H13N3O6.2Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XL6BJI034, chemically known as benzoic acid, 5-((1e)-(4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt, dihydrate, but more generally known as balsalazide sodium, which bears US NIH Compound Identifier 6504526.

European Medicines Agency schedules balsalazide sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06092MIG. Most nations, for tariff purposes, schedule balsalazide sodium under HS 29270000. SMILES: C1CC(CCC1C(=O)NCCC(=O)[O-])/N=N/C2CCC(C(C2)C(=O)[O-])O.O.O.[NA+].[NA+].

UNSPSC 51386404 Balsalazide sodium is a Commodity code that appears to cover pharmaceutical active ingredients, but the single recent state and local solicitation tagged to it—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—does not involve balsalazide or any related ulcerative-colitis therapeutic. The mismatch suggests either a classification error in the county's procurement system or that this code sees minimal relevant state and local activity. The solicitation itself is genuine: Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Responses were due July 26, 2023 (a date that has passed). The county required e-procurement portal submission, included delivery and shipping costs in bid pricing, mandated drug-free workplace and E-Verify compliance, and structured the contract with an initial two-year term plus one-year renewal option. FEMA funding was cited, introducing Clean Air Act and Federal Water Pollution Control Act compliance obligations.

Because only one opportunity appears in the recent-activity block and that opportunity involves naloxone procurement rather than balsalazide, this code shows no measurable activity in genuine balsalazide pharmaceutical procurement at the state and local level. A business development professional evaluating this code should verify whether recent opportunities are being correctly tagged to it or whether state and local agencies are sourcing balsalazide through pharmaceutical wholesalers, group purchasing organizations, or federal contracts rather than direct public solicitations.